Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Volume: 370, Issue: 4, Pages: 322 - 333
Published: Jan 23, 2014
Abstract
Background null Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. null Methods null We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) e4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with...
Paper Details
Title
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Published Date
Jan 23, 2014
Volume
370
Issue
4
Pages
322 - 333
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.